Qudexy XR Approval History
- FDA approved: Yes (First approved March 11th, 2014)
- Brand name: Qudexy XR
- Generic name: topiramate
- Dosage form: Extended-Release Capsules
- Company: Upsher-Smith Laboratories Inc.
- Treatment for: Seizures, Lennox-Gastaut Syndrome, Migraine Prevention
Qudexy XR (topiramate) is an antiepileptic drug indicated for the treatment of partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut Syndrome in adults and children; and for the prophylaxis of migraine headache in adults and adolescents.
Development History and FDA Approval Process for Qudexy XR
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.